Category Archives: Global News Feed

All director nominees reelected for the coming yearAll other proposals also approved by shareholders

See the article here:
Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors

WOBURN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (“ISBP”) 2022 Conference. The event is taking place September 12 through September 16, 2022 in Sion, Switzerland.

Link:
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the ISBP 2022...

CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Link:
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

nicox saInterim Consolidated statement of Comprehensive Income

More:
Nicox Provides First Half 2022 Business Update and Financial Results

LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.

Read the original here:
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test.

Read more here:
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the...

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.

Read the original post:
Vaccitech to Present at Upcoming September Investors Conferences

Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 half-year financial results on Thursday, September 22, 2022.

Read the original here:
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

FOSTER CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 2:00 p.m. ET.

Read more:
Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 10:30 a.m. ET.

Read the original post:
Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference